Paragraph IV Certifications: How Generic Drug Companies Legally Challenge Patents
Paragraph IV certifications let generic drug makers legally challenge brand-name patents before launching their products. This Hatch-Waxman Act mechanism saves billions annually by speeding up generic access, but it's a high-stakes legal battle with big risks and huge rewards.
Continue reading...